UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib

@article{MezaJunco2009UGT1A1PA,
  title={UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib},
  author={Judith Meza-Junco and Quincy S.-C. Chu and O. E. Christensen and P. Rajagopalan and Soma Das and Ruslan Stefanyschyn and Michael B Sawyer},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2009},
  volume={65},
  pages={1-4}
}
To report a single case of uridine glucuronosyltransferase 1A1 (UGT1A1) polymorphism and hyperbilirubinemia in a patient who received sorafenib. A 63-year-old man with cirrhosis was diagnosed with hepatocellular carcinoma. His cirrhosis was categorized as Child-Pugh A, total bilirubin concentration was 24 μmol/L (normal range <20 μmol/L). The patient was enrolled in a phase I trial combination study of cyclophosphamide and doxorubicin combined with sorafenib. After a single infusion of… CONTINUE READING
22 Extracted Citations
23 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 22 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 23 references

Is sorafenib (S) safe and eVective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis

  • GK Abou-Alfa, D Amadori, A Santoro
  • J Clin Oncol
  • 2008
1 Excerpt

Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma

  • A Cheng, Y Kang, Z Chen
  • J Clin Oncol
  • 2008
1 Excerpt

Similar Papers

Loading similar papers…